The following is a summary of the Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript:
Financial Performance:
In Q3 2024, GAAP costs and expenses increased by $2.4 million to $13.7 million, primarily driven by an increase in non-cash stock-based compensation, reaching $3 million.
Non-GAAP costs and expenses were up $1.2 million, reaching $10.4 million.
GAAP net loss widened in Q3 2024 to $12.7 million, up from $10.6 million a year earlier, whereas the non-GAAP net loss increased to $9.4 million from $8.5 million.After completing a rights offering in July, raising $60 million, cash and equivalents stood at $79 million as of September 30, 2024.
Business Progress:
Pulse Biosciences achieved significant clinical advancements with their proprietary Nano-PFA technology in treating Atrial Fibrillation and other soft tissue conditions.
Received U.S. FDA breakthrough device designation for their Cardiac Surgical System and launched pivotal studies to support future commercial applications.
Expanded the pilot program under no-cost evaluation agreements in the U.S. to further refine procedural techniques using nano-PFA for benign thyroid nodules treatment.
Opportunities:
The use of nano-PFA in treating benign thyroid nodules presents a market potential exceeding $1 billion annually, with promising early clinical experiences underlining the technology's potential to offer minimally invasive and effective treatment solutions.
Increased focus on cardiological applications, particularly through nano-PFA-enhanced catheters and surgical systems, aimed at significant improvements in patient outcomes in Atrial Fibrillation treatments.
Risks:
The nano-PFA technology's adoption and efficacy are still being evaluated in clinical settings, requiring further evidence to establish its superiority and safety over existing treatment options.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
